



Innovative Peptide Solutions for Cell- & Immunotherapy



Clinical Peptides

Largest Variety of Peptide
Formats for Development of

- ❖ Adoptive cell transfer
- ❖ *Ex vivo* dendritic cell pulsing
- ❖ Peptide vaccination strategies
- ❖ Clinical immune monitoring
- ❖ Immune diagnostic development

Contact us for further information: peptide@jpt.com

JPT Peptide Technologies
www.jpt.com
peptide@jpt.com

Contact
T +49-30-6392-7878
F +49-30-6392-7888

USA/Canada
T 1-888-578-2660
F 1-888-578-2666



Innovative Peptide Solutions

Supporting the Paradigm Shift in Immunotherapy

JPT's Clinical Peptides – Much More than a Fee for Service

The development of cell- and immunotherapy concepts creates an increasing demand for synthetic peptides, matching both regulatory and quality criteria as well as the need for rapid accessibility and cost effectiveness. Together with its partners JPT developed a production environment with critical quality measures beyond ISO 9001 for the stringent requirements in clinical development resulting in two different peptide qualities, Clinical Grade and ISO PLUS.

Our Support Includes

- Peptide design
- Manufacturability assessment
- Stability and solubility testing
- IND and CMC support
- CoA's and full analytical coverage
- Batch release
- Site visits and audits welcome

Clinical Immunotherapy Trials Applying Peptides

Details: <https://clinicaltrials.gov>

NCT02721043 / NCT01333046 / NCT02510417
NCT03223103 / NCT02933073 / NCT02231853
NCT02332889 / NCT03091933 / NCT03215004

Selected References

- "Autologous Adoptive T-Cell Therapy for Recurrent or Drug-Resistant Cytomegalovirus Complications in Solid Organ Transplant Patients: A Single-Arm Open-Label Phase I Clinical Trial"
Smith et al., CID (2018)
- "Safety, Immune and Clinical Responses in Metastatic Melanoma Patients Vaccinated with a Long Peptide Derived from Indoleamine 2,3-Dioxygenase in Combination with Ipilimumab"
Bjoern et al., Cytotherapy (2016)
- "Broadly-Specific Cytotoxic T Cells Targeting Multiple HIV Antigens are Expanded from HIV+ Patients: Implications for Immunotherapy"
Lam et al., Molecular Therapy (2015)



“We recently demonstrated the feasibility and clinical benefit associated with the infusion of rapidly generated single-culture VSTs, manufactured using JPT's Clinical Grade PepMix™ Peptide Pools covering 12 immunogenic antigens from five viruses (EBV, AdV, CMV, BK, and HHV6). When administered to 11 allogeneic stem cell transplant recipients, 8 of whom had up to four active infections, these VSTs produced an overall 94% response rate.”

Ann Leen, PhD, Baylor College of Medicine, Houston, TX, USA

Disclaimer: JPT does not warrant that any products are applicable in clinical applications. JPT invites you to audit its facilities and decide if Clinical Grade or ISO PLUS peptides are suited for a specific application.

Issue Date: October 2020

JPT Peptide Technologies
www.jpt.com
peptide@jpt.com

Contact
T +49-30-6392-7878
F +49-30-6392-7888

USA/Canada
T 1-888-578-2660
F 1-888-578-2666

jpt

Innovative Peptide Solutions